Encelimab Antibody

Encelimab, an anti-LAG3 monoclonal antibody, blocks LAG-3 binding to MHC class II, promoting T-cell activation and anti-tumor immunity. It demonstrates preclinical efficacy by reducing tumor burden in lymphoma models like A20 xenografts, both as monotherapy and with anti-PD-1, supporting cancer immunotherapy research.